Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Niklas Beumer
DNA hypomethylation traits define human regulatory T cells in cutaneous tissue and identify their blood recirculating counterparts - Nature Immunology
Abstract CD4+ regulatory T (Treg) cells in tissues play crucial immunoregulatory and regenerative roles. Despite their importance, the epigenetics and differentiation of human tissue Treg cells are incompletely understood. Here, we performed genome-wide DNA methylation analysis of human Treg cells from skin and blood and integrated these data into a multiomic framework, including chromatin accessibility and gene expression.
Induced regulatory T cells for therapy: targeting RBPJ to enhance stability and function - Signal Transduction and Targeted Therapy
In a recent study published in Nature, Chen et al.1 investigated the potential of RBPJ knock-out to improve stability and function of induced regulatory T cells (iTreg cells). This finding could further enhance the utilization of these cells for adoptive immunotherapy in immune-related diseases. Regulatory T cells (Treg cells) play a crucial role in maintaining immune homeostasis. They are a subset of CD4-positive T cells that are selected as self-reactive clones during thymic maturation.
Single-cell chromatin landscape and DNA methylation patterns reveal shared molecular programs in human tumor and non-tumor tissue CCR8+ Treg cells
Abstract Regulatory T (Treg) cells, a subset of CD4+ T cells, play a crucial role in immunoregulation. Notably, CCR8-expressing Treg cells in tissues also contribute to organ homeostasis and repair. To determine whether these tissue-regenerative programs are active in the tumor microenvironment, we employed single-cell chromatin accessibility and genome-wide DNA methylation analyses to investigate CCR8+ tissue Treg cells isolated from human tumor and adjacent tumor-free tissues.
Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial | Nature Communications
Abstract Beyond first line, the prognosis of relapsed/refractory (R/R) acute myeloid leukemia (AML) patients is poor with limited treatment options. Bemcentinib is an orally bioavailable, potent, highly selective inhibitor of AXL, a receptor tyrosine kinase associated with poor prognosis, chemotherapy resistance and decreased antitumor immune response.
Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapy - Nature Communications
Abstract The long-term consequences of cancer and its therapy on the patients’ immune system years after cancer-free survival remain poorly understood. Here, we present an in-depth characterization of the bone marrow immune ecosystem of multiple myeloma long-term survivors, from initial diagnosis up to 17 years following a single therapy line and cancer-free survival.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Niklas
Contact Niklas, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack